Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria

International Journal of Antimicrobial Agents

Volumn 7, Issue 1, 1996, Pages 9-14

  Omri, A ^a,b,c   Ravaoarinoro, M ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c DEF AND CIV INST OF ENVIRON MED   (Canada)

Author keywords

Aminoglycosides; Bacteria; Liposomes

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; LIPOSOME; NETILMICIN; TOBRAMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0029896310     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(96)00003-9     Document Type: Article

References (27)

1. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990; 88(suppl C):16S-20S.
2. De Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80(suppl 6 B):115-118.
3. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:797-800.
4. Govaerts PJ, Claes J, van De Heyning PH, Jorens PG, Marquet J, De Broe ME. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990;52:227-251.
5. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984;101:92-104.
6. Talbot PA. Potentiation of aminoglycoside-induced blockade by protons in vitro and in vivo. J Pharmacol Exp Ther 1987;241:686-694.
7. Shannon K, Phillips I. Mechanisms of resistance to aminoglycosides in clinical isolates. J Antimicrob Chemother 1982;9:91-102.
8. Young EJ, Sewell CM, Koza MA, Clarridge JE. Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sci 1985;290:223-227.
9. Ravaoarinoro M, Toma E. Les liposomes dans le traitement des infections. Ann Med Intern 1993;144:182-187.
10. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagacé J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:1090-1095.
11. Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis 1992;15:654-667.
12. Nacucchio MC, Gatto Bellora MJ, Sordelli DO, D'Aquino M. Enhanced liposome-mediated antibacterial activity of piperacillin and gentamicin against Gram-negative bacilli in vitro. J Microencapsul 1988;5:303-309.
13. Ravaoarinoro M, Toma E, Agbaba O, Morisset R. Efficient entrapment of amikacin and teicoplanin in liposomes. J Drugs Targeting 1993;1:191-195.
14. Wilcox MH, Schumacher-Perdreau F. Lack of evidence for increased adherent growth in broth or human serum of clinically significant coagulase-negative staphylococci. J Hospital Infect 1994;26:239-250.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd edition. Approved standard M7-A2. NCCLS, Villanova, PA, 1990.
16. Poyner EA, Alpar HO, Brown MRW. Preparation, properties and the effects of free and liposomal tobramycin on siderophore production by Pseudomonas aeruginosa. J Antimicrob Chemother 1994;34:43-52.
17. Mayhew E, Ito M, Lazo R. Toxicity of non drug containing liposomes for cultured human cells. Exp Cell Res 1987;171:195-202.
18. Allen TM, Cleland LG. Serum-induced leakage of liposome contents. Biochim Biophys Acta 1980;597:418-426.
19. Kirby C, Clarke J, Gregoriadis G. Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett 1980;111:324-328.
20. Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982;30:2123-2136.
21. Bakker-Woudenberg IAJM, Lokerse AF, Vink van den Berg JC, Roerdink FH, Michel MF. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother 1986;30:295-300.
22. Hodges NA, Mounajed R, Olliff CJ, Padfield JM. The enhancement of neomycin activity on Escherichia coli by entrapment in liposomes. J Pharm Pharmacol 1979;31(suppl.):85P.
23. Stevenson M, Baillie AJ, Richards RME. Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774.2 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother 1983;24:742-749.
24. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 1991;8:1079-1086.
25. Fountain MW, Dees C, Schultz RD. Enhanced intracellular killing of Staphylococcus aureus by canine monocytes treated with liposomes containing amikacin, gentamicin, kanamycin, and tobramycin. Current Microbiol 1981;6:373-376.
26. Fountain MW, Weiss SK, Fountain AG, Shen A, Lenk RP. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis 1985;152:529-535.
27. Bonventre PF, Greogoriadis G. Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped with liposomes. Antimicrob Agents Chemother 1978;13:1049-1051.